Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.49 |
| ▸ | NPY1R | P25929 | 6/20 | 0.49 |
| ▸ | NPY2R | P49146 | 4/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | OTC | P00480 | 1/20 | 0.40 |
| ▸ | NRP1 | O14786 | 1/20 | 0.39 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288598 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL31174187 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29358630 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL288599 | 1.00 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL10001721 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL31264971 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29947272 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL12533211 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30483977 | 0.97 | NPY4R (0.50) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29769333 | 0.97 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119496-A1 | INHIBITORS OF CYSTEINE PEPTIDASES ISOLATED FROM NATURAL RAW MATERIALS AND USE OF THE INHIBITORS IN MEDICINE AND VETERINARY MEDICINE | RAPAK, Andrzej Marek (PL) | 2022-04-21 | — | — | US | disclosed |
| WO-2015171516-A1 | COMPOSITIONS AND METHODS RELATING TO IONIC SALTS OF PEPTIDES | THETIS PHARMACEUTICALS LLC (US) | 2015-11-12 | — | — | WO | disclosed |
| CN-102317283-A | Novel CC-1065 analogs and conjugates thereof | SYNTARGA BV | 2012-01-11 | — | — | CN | disclosed |
| US-20020168337-A1 | Sustained-release preparation | TAKADA CHEMICAL INDUSTRIES LTD. | 2002-11-14 | — | — | US | disclosed |
| US-20020058622-A1 | Sustained-release preparation | IGARI YASUTAKA (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6376461-B1 | WATER INSOLUBLE OR SLIGHTLY WATER SOLUBLE POLYVALENT METAL SALT OF A GROWTH HORMONE, AND A BIODEGRADABLE POLYMER; ENDOTHELIN ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-6087324-A | A WATER-INSOLUBLE OR A SLIGHTLY WATER-SOLUBLE POLYVALENT METAL SALT OF A WATER-SOLUBLE PHYSIOGICALLY ACTIVE PEPTIDE WHICH IS NOT AN ENDOTHELIN ANTAGONIST, AND A BIODEGRADABLE POLYMER SUCH AS COPOLYMER OF GLYCOLIC AND LACTIC ACID | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| CN-1109780-A | Sustained-release preparation of anti-endothelin substance | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1995-10-11 | — | — | CN | disclosed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020168337-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | NPY4R 789/4885NPY1R 118/4885NPY2R 273/4885 |
| US-20020058622-A1 | Sustained-release preparation | EDNRA, EDNRB, ORAI1 | NPY4R 789/4885NPY1R 118/4885NPY2R 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.